Tempus Ai Cl A (TEM)

$89.23 +2.19 (2.52%)
Market Cap 15.12B
Revenue (ttm) 693.40M
Net Income (ttm) -705.81M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -101.79%
Debt to Equity Ratio 1.85
Volume 4,617,800
Avg Vol 8,986,958
Day's Range N/A - N/A
Shares Out 173.73M
Stochastic %K 48%
Beta 4.87
Analysts Sell
Price Target $85.42

Company Profile

Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services...

Industry: Health Information Services
Sector: Healthcare
Phone: 800 976 5448
Fax: 800 893 0276
Address:
600 West Chicago Avenue, Suite 510, Chicago, United States
ScreamLikeABaby
ScreamLikeABaby Oct. 24 at 9:46 PM
$TEM Next week is gonna be fun 🚀
0 · Reply
AlexSwiss77
AlexSwiss77 Oct. 24 at 9:09 PM
$TEM consolidating the 90$ area before breaking 100$ like $BE did
0 · Reply
abubnic
abubnic Oct. 24 at 6:01 PM
$TEM My husband needed genetic testing to determine the best course of action for immunotherapy with a rare cancer. It required a special kit. I flipped the kit over and caught the address on the mail label. Happy to recognize the company as a stock I own. This is the future of medicine—and the present: precision medicine. They have one of the world's largest libraries of multimodal data, which includes clinical and genomic information from millions of de-identified patient records. This data is used to train its AI models.
2 · Reply
paaps
paaps Oct. 24 at 5:35 PM
$TEM This will fly if the vol. picks up
0 · Reply
icebrian
icebrian Oct. 24 at 2:51 PM
$TEM Just bought more
0 · Reply
ScreamLikeABaby
ScreamLikeABaby Oct. 24 at 1:52 PM
$TEM Rock n Roll 🎸 🎸 🎸
0 · Reply
Bank1986
Bank1986 Oct. 24 at 1:48 PM
$TEM Please close over $90 today! GLTA
0 · Reply
ProfitablePatterns
ProfitablePatterns Oct. 24 at 12:59 PM
$TEM offering a low risk entry here at converging trendline and 50 day ema support. I am long
0 · Reply
paaps
paaps Oct. 24 at 12:36 PM
$TEM Today we might see $93🤞
0 · Reply
TheFamilyOffice
TheFamilyOffice Oct. 24 at 8:23 AM
$TEM imagine of this era is the last time we see Tempus below 100
1 · Reply
Latest News on TEM
Tempus to Report Third Quarter 2025 Financial Results on November 4

Oct 21, 2025, 8:30 AM EDT - 3 days ago

Tempus to Report Third Quarter 2025 Financial Results on November 4

Ambry Genetics Announces 10-Year Study in Genetics in Medicine Highlighting the Impact of Proactive Exome Reanalysis for Healthcare Equity

Oct 20, 2025, 9:00 AM EDT - 4 days ago

Ambry Genetics Announces 10-Year Study in Genetics in Medicine Highlighting the Impact of Proactive Exome Reanalysis for Healthcare Equity

Tempus Announces Collaboration with Whitehawk Therapeutics to Advance Biomarker-Driven Oncology Research

Oct 16, 2025, 8:30 AM EDT - 8 days ago

Tempus Announces Collaboration with Whitehawk Therapeutics to Advance Biomarker-Driven Oncology Research

WHWK

Tempus Announces Six Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025

Oct 15, 2025, 8:30 AM EDT - 9 days ago

Tempus Announces Six Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025

Tempus Selected by ARPA-H to Provide CRO and Testing Services for the ADAPT Program, Advancing Precision Cancer Therapy

Oct 9, 2025, 8:30 AM EDT - 15 days ago

Tempus Selected by ARPA-H to Provide CRO and Testing Services for the ADAPT Program, Advancing Precision Cancer Therapy

Tempus AI's $100 Breakout — Billionaire Cliff Asness Reaps 60% Windfall

Oct 9, 2025, 8:24 AM EDT - 15 days ago

Tempus AI's $100 Breakout — Billionaire Cliff Asness Reaps 60% Windfall

Ambry Genetics Announces Improved EHR-Integrated Breast Cancer Risk Assessment Solution with Upgraded Tyrer-Cuzick Scoring Approach Incorporating Breast Density

Oct 1, 2025, 12:24 PM EDT - 23 days ago

Ambry Genetics Announces Improved EHR-Integrated Breast Cancer Risk Assessment Solution with Upgraded Tyrer-Cuzick Scoring Approach Incorporating Breast Density

Overlooked Stock: TEM Taps All-Time High on FDA Clearance

Sep 22, 2025, 4:30 PM EDT - 4 weeks ago

Overlooked Stock: TEM Taps All-Time High on FDA Clearance

Tempus Receives U.S. FDA 510(k) Clearance for Tempus xR IVD, its RNA NGS In Vitro Diagnostic Device

Sep 22, 2025, 8:30 AM EDT - 4 weeks ago

Tempus Receives U.S. FDA 510(k) Clearance for Tempus xR IVD, its RNA NGS In Vitro Diagnostic Device

Renalytix Announces Collaboration with Tempus to Advance Intelligent Risk Assessment in Diabetic Kidney Disease

Sep 15, 2025, 8:00 AM EDT - 5 weeks ago

Renalytix Announces Collaboration with Tempus to Advance Intelligent Risk Assessment in Diabetic Kidney Disease

Tempus AI stock is cheap as Murrey Math Lines points to more gains

Sep 12, 2025, 1:09 PM EDT - 6 weeks ago

Tempus AI stock is cheap as Murrey Math Lines points to more gains

Tempus AI: Is TEM Stock A 10x Growth Story?

Sep 12, 2025, 10:05 AM EDT - 6 weeks ago

Tempus AI: Is TEM Stock A 10x Growth Story?

Tempus AI Gains FDA Clearance For Updated Pixel To Boost Accuracy And Efficiency In Cardiac Imaging

Sep 11, 2025, 1:58 PM EDT - 6 weeks ago

Tempus AI Gains FDA Clearance For Updated Pixel To Boost Accuracy And Efficiency In Cardiac Imaging

Tempus Receives U.S. FDA Special 510(k) Clearance for Updated Tempus Pixel Device

Sep 11, 2025, 8:30 AM EDT - 6 weeks ago

Tempus Receives U.S. FDA Special 510(k) Clearance for Updated Tempus Pixel Device

Tempus Announces New Study in JCO Precision Oncology Validating PurIST® Algorithm for Enhanced Therapy Selection in Pancreatic Cancer

Sep 9, 2025, 8:30 AM EDT - 6 weeks ago

Tempus Announces New Study in JCO Precision Oncology Validating PurIST® Algorithm for Enhanced Therapy Selection in Pancreatic Cancer

Tempus AI, Inc. (TEM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 8, 2025, 4:25 PM EDT - 6 weeks ago

Tempus AI, Inc. (TEM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

After An Odd Start, Tempus AI Is Making A Beeline To The Good End Of The AI Rainbow

Sep 8, 2025, 10:58 AM EDT - 6 weeks ago

After An Odd Start, Tempus AI Is Making A Beeline To The Good End Of The AI Rainbow

Tempus AI: Evolving To Data Infrastructure And Monetization Options Platform

Sep 8, 2025, 4:43 AM EDT - 6 weeks ago

Tempus AI: Evolving To Data Infrastructure And Monetization Options Platform

Tempus AI: Strategic AI Advancements In Precision Oncology With Solid Stock Upside Potential

Sep 8, 2025, 2:35 AM EDT - 6 weeks ago

Tempus AI: Strategic AI Advancements In Precision Oncology With Solid Stock Upside Potential

Tempus AI: Expansive Opportunity As Healthcare Becomes More Heavily Scrutinized

Sep 4, 2025, 2:33 PM EDT - 7 weeks ago

Tempus AI: Expansive Opportunity As Healthcare Becomes More Heavily Scrutinized

Northwestern Medicine Becomes First Health System to Integrate Tempus' Generative AI Co-Pilot, David, Into Its EHR Platform

Sep 4, 2025, 8:30 AM EDT - 7 weeks ago

Northwestern Medicine Becomes First Health System to Integrate Tempus' Generative AI Co-Pilot, David, Into Its EHR Platform

Tempus to Participate in Morgan Stanley's 23rd Annual Global Healthcare Conference

Sep 3, 2025, 4:01 PM EDT - 7 weeks ago

Tempus to Participate in Morgan Stanley's 23rd Annual Global Healthcare Conference

Tempus Announces the Acquisition of Paige

Aug 22, 2025, 9:20 AM EDT - 2 months ago

Tempus Announces the Acquisition of Paige

Tempus AI: TEM Stock To $130?

Aug 18, 2025, 9:24 AM EDT - 2 months ago

Tempus AI: TEM Stock To $130?

Cathie Wood's Top 10 Stock Picks: Unpacking Ark Funds Innovation Picks For The Next Decade

Aug 14, 2025, 1:02 PM EDT - 2 months ago

Cathie Wood's Top 10 Stock Picks: Unpacking Ark Funds Innovation Picks For The Next Decade

AMD ARKF ARKG ARKK ARKQ ARKW ARKX

Tempus AI Stock: Is It A Buy Following Guidance Raise?

Aug 12, 2025, 7:45 AM EDT - 2 months ago

Tempus AI Stock: Is It A Buy Following Guidance Raise?

TEM Investors Have Opportunity to Join Tempus AI, Inc. Fraud Investigation with the Schall Law Firm

Aug 12, 2025, 4:42 AM EDT - 2 months ago

TEM Investors Have Opportunity to Join Tempus AI, Inc. Fraud Investigation with the Schall Law Firm

Tempus AI: Buy or Sell TEM Stock At $65?

Aug 11, 2025, 10:25 AM EDT - 2 months ago

Tempus AI: Buy or Sell TEM Stock At $65?

Tempus AI, Inc. (TEM) Q2 2025 Earnings Call Transcript

Aug 8, 2025, 11:18 AM EDT - 2 months ago

Tempus AI, Inc. (TEM) Q2 2025 Earnings Call Transcript

TEM Earnings Rally: A.I. Use in Health Care, Drug Discovery

Aug 8, 2025, 9:16 AM EDT - 2 months ago

TEM Earnings Rally: A.I. Use in Health Care, Drug Discovery

Tempus Reports Second Quarter 2025 Results

Aug 8, 2025, 6:00 AM EDT - 2 months ago

Tempus Reports Second Quarter 2025 Results

Tempus AI Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Aug 8, 2025, 2:34 AM EDT - 2 months ago

Tempus AI Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Tempus AI: Next Leg Up

Jul 31, 2025, 2:32 PM EDT - 3 months ago

Tempus AI: Next Leg Up

Tempus AI: Data‑Driven Margin Lift, But Cash Burn Extends My Hold Stance

Jul 30, 2025, 2:25 AM EDT - 3 months ago

Tempus AI: Data‑Driven Margin Lift, But Cash Burn Extends My Hold Stance

Tempus AI: Sustaining Growth Momentum With Acquisitions & Partnerships

Jul 29, 2025, 9:25 AM EDT - 3 months ago

Tempus AI: Sustaining Growth Momentum With Acquisitions & Partnerships

Tempus to Report Second Quarter 2025 Financial Results on August 8

Jul 22, 2025, 8:30 AM EDT - 3 months ago

Tempus to Report Second Quarter 2025 Financial Results on August 8

Tempus Receives U.S. FDA 510(k) Clearance for Tempus ECG-Low EF Software

Jul 16, 2025, 8:00 AM EDT - 3 months ago

Tempus Receives U.S. FDA 510(k) Clearance for Tempus ECG-Low EF Software

Apple Acquisition Buzz: Its $60 Billion War Chest Is Enough To Buy Datadog And Tempus

Jul 10, 2025, 12:15 PM EDT - 3 months ago

Apple Acquisition Buzz: Its $60 Billion War Chest Is Enough To Buy Datadog And Tempus

AAPL DDOG

Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients

Jul 9, 2025, 4:00 PM EDT - 3 months ago

Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients

PSNL

Tempus Expands AI-Enabled Care Pathway Intelligence Platform into Breast Cancer

Jul 8, 2025, 8:30 AM EDT - 3 months ago

Tempus Expands AI-Enabled Care Pathway Intelligence Platform into Breast Cancer

Tempus AI: High-Growth And High-Risk

Jul 1, 2025, 2:48 PM EDT - 4 months ago

Tempus AI: High-Growth And High-Risk

Tempus Announces Pricing of Upsized Offering of $650 Million of Convertible Senior Notes

Jun 30, 2025, 10:43 PM EDT - 4 months ago

Tempus Announces Pricing of Upsized Offering of $650 Million of Convertible Senior Notes

Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense

Jun 30, 2025, 7:00 AM EDT - 4 months ago

Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense

Ambry Genetics' CARE Program Validated for Accuracy in Identifying High-Risk Patients for Hereditary Cancer Testing

Jun 25, 2025, 5:00 PM EDT - 4 months ago

Ambry Genetics' CARE Program Validated for Accuracy in Identifying High-Risk Patients for Hereditary Cancer Testing

Tempus AI Is Well Worth Its Price Tag

Jun 25, 2025, 8:07 AM EDT - 4 months ago

Tempus AI Is Well Worth Its Price Tag

Tempus to Participate in TD Cowen's 4th Annual Tools/Dx Revolution Conference

Jun 17, 2025, 8:30 AM EDT - 4 months ago

Tempus to Participate in TD Cowen's 4th Annual Tools/Dx Revolution Conference

Shamis & Gentile, P.A. Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Tempus AI, Inc. and Sets a Lead Plaintiff Deadline of August 12, 2025

Jun 13, 2025, 3:00 PM EDT - 4 months ago

Shamis & Gentile, P.A. Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Tempus AI, Inc. and Sets a Lead Plaintiff Deadline of August 12, 2025

ScreamLikeABaby
ScreamLikeABaby Oct. 24 at 9:46 PM
$TEM Next week is gonna be fun 🚀
0 · Reply
AlexSwiss77
AlexSwiss77 Oct. 24 at 9:09 PM
$TEM consolidating the 90$ area before breaking 100$ like $BE did
0 · Reply
abubnic
abubnic Oct. 24 at 6:01 PM
$TEM My husband needed genetic testing to determine the best course of action for immunotherapy with a rare cancer. It required a special kit. I flipped the kit over and caught the address on the mail label. Happy to recognize the company as a stock I own. This is the future of medicine—and the present: precision medicine. They have one of the world's largest libraries of multimodal data, which includes clinical and genomic information from millions of de-identified patient records. This data is used to train its AI models.
2 · Reply
paaps
paaps Oct. 24 at 5:35 PM
$TEM This will fly if the vol. picks up
0 · Reply
icebrian
icebrian Oct. 24 at 2:51 PM
$TEM Just bought more
0 · Reply
ScreamLikeABaby
ScreamLikeABaby Oct. 24 at 1:52 PM
$TEM Rock n Roll 🎸 🎸 🎸
0 · Reply
Bank1986
Bank1986 Oct. 24 at 1:48 PM
$TEM Please close over $90 today! GLTA
0 · Reply
ProfitablePatterns
ProfitablePatterns Oct. 24 at 12:59 PM
$TEM offering a low risk entry here at converging trendline and 50 day ema support. I am long
0 · Reply
paaps
paaps Oct. 24 at 12:36 PM
$TEM Today we might see $93🤞
0 · Reply
TheFamilyOffice
TheFamilyOffice Oct. 24 at 8:23 AM
$TEM imagine of this era is the last time we see Tempus below 100
1 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 24 at 5:06 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $TEM Current Share Price: $88.25 Contracts: $TEM January 15, 2027 $90 Calls Scale in: $26.44- $32.31 Scale out: $41.12-$52.88 Can Easily Capture: 60% ROI Blended DTE: 449 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
Alixc
Alixc Oct. 24 at 4:11 AM
$TEM drop a good news and its go mode
0 · Reply
ScreamLikeABaby
ScreamLikeABaby Oct. 24 at 12:26 AM
$TEM A significant beat on earnings would make a short squeeze a strong possibility 🤞
0 · Reply
OptionzGuru
OptionzGuru Oct. 23 at 7:50 PM
$TEM entered here for a swing
0 · Reply
blindoptimist95
blindoptimist95 Oct. 23 at 7:33 PM
$TEM looking strong
1 · Reply
Parnell8
Parnell8 Oct. 23 at 6:32 PM
$TEM $90 next level to short, algos got this until then
0 · Reply
Mountainbiker168
Mountainbiker168 Oct. 23 at 4:32 PM
$TEM Max load
0 · Reply
Thelonius_Stonk
Thelonius_Stonk Oct. 23 at 3:10 PM
$TEM couple nice wicks off the 50d prob nothing
0 · Reply
ScreamLikeABaby
ScreamLikeABaby Oct. 23 at 3:09 PM
$TEM Never bet against BlackRock As of the second quarter of 2025, BlackRock, Inc. owns 4,139,428 shares of Tempus AI, Inc. (NASDAQ: TEM). This stake was valued at approximately $263 million based on the stock's price at the time of the SEC filing. Key details from BlackRock's August 2025 SEC filing: The firm significantly increased its position, showing a 553.87% rise in its holdings during the second quarter. BlackRock is one of the largest institutional investors in Tempus AI, along with firms like Baillie Gifford and the Vanguard Group.
0 · Reply
TheProphetOfProfit
TheProphetOfProfit Oct. 23 at 2:19 PM
$TEM nearing multi-month uptrend support on the daily, looks like a solid add off the $82-$83 area.
0 · Reply
ScreamLikeABaby
ScreamLikeABaby Oct. 23 at 1:55 PM
$TEM
0 · Reply
SniggleFritz
SniggleFritz Oct. 23 at 9:42 AM
$TEM testing channel support at $85—bullish setup! Bounce likely to $95-$100 with FDA wins & ARPA-H deal. Analysts target $98-$100. Long above $86
0 · Reply